Daré Bioscience Advances Phase 2 Trial for First FDA-Approved HPV Treatment
Event summary
- Daré Bioscience initiates Phase 2 trial for DARE-HPV, a novel treatment for persistent high-risk HPV infection, with topline data expected in 2027.
- The study is a randomized, placebo-controlled, double-blind trial involving approximately 100 women with persistent high-risk HPV infection.
- DARE-HPV is backed by a $10 million ARPA-H-funded contract, with $9 million already received and the remainder contingent on program milestones.
- If successful, DARE-HPV could be the first FDA-approved pharmacologic treatment for HPV infection, addressing a substantial unmet medical need.
The big picture
Daré Bioscience's Phase 2 trial for DARE-HPV marks a significant step in addressing the unmet need for pharmacologic treatments for high-risk HPV infection. Currently, the standard of care relies on monitoring and surgical interventions, which carry risks of preterm birth and fertility impacts. If successful, DARE-HPV could redefine cervical disease prevention by targeting the virus itself, potentially reducing the need for costly and burdensome 'watchful waiting' visits. The trial is supported by a $10 million ARPA-H contract, highlighting the strategic importance of advancing women's health innovations.
What we're watching
- Regulatory Pathway
- Whether DARE-HPV can navigate the FDA's 505(b)(2) pathway for approval, given the lack of precedent for HPV treatments.
- Clinical Success
- The pace at which DARE-HPV demonstrates safety and efficacy in clearing high-risk HPV infection, as measured by the primary endpoint of HPV clearance rate at three months post-treatment.
- Market Potential
- How DARE-HPV's potential approval could reshape the treatment paradigm for cervical disease prevention, addressing a market with over 6 million new high-risk HPV infections annually in the U.S.
Related topics